Athira Pharma IncChange company Symbol lookupSelect an option...ATHA Athira Pharma IncHLTH Cue Health IncBRFH Barfresh Food Group IncNEOV NeoVolta IncFIISO Financial Institutions IncKA Kineta IncTCS Container Store Group IncMLGO MicroAlgo IncINDI indie Semiconductor IncJCI Johnson Controls International PLCGo
Change company Symbol lookup
Select an option...
ATHA Athira Pharma Inc
HLTH Cue Health Inc
BRFH Barfresh Food Group Inc
NEOV NeoVolta Inc
FIISO Financial Institutions Inc
KA Kineta Inc
TCS Container Store Group Inc
MLGO MicroAlgo Inc
INDI indie Semiconductor Inc
JCI Johnson Controls International PLC
Health Care : Pharmaceuticals | Small Cap Value
Company profileAthira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and stop neurodegeneration. Its pipeline consists of both blood brain barrier (BBB) permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system (PNS), and other indications. Its lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, small molecule positive modulator of the hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) system for CNS disorders. It is also advancing potential drug candidates for neuropathic pain, amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases. Its neuropathic pain drug candidate, ATH-1020, completed a Phase I single ascending dose evaluation in healthy volunteers. Its ATH-1105 is a small molecule compound designed to be an orally available, once-daily treatment to enhance the HGF/MET system.
|
|
|
|
| |
| Latest Earnings (Q2 ending 06/2023) | Upcoming Announcement (Q3 ending 09/2023) | ||||||
|---|---|---|---|---|---|---|---|
| Q2 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. | -$0.78 | Estimate increased in year leading up to announcement | 0.93% | Q3 consensus estimate | -$0.81 | Q3 consensus estimate is lower than previous yr's Q3 actual | -53.58% |
| Q2 Consensus estimate | -$0.78 | Previous year's Q3 actual | -$0.53 | ||||
Quarterly Consensus Estimate Trends over Time
ATHA's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.